These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 18220512

  • 1. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell.
    Gozes I, Divinski I.
    Curr Alzheimer Res; 2007 Dec; 4(5):507-9. PubMed ID: 18220512
    [Abstract] [Full Text] [Related]

  • 2. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.
    Gozes I, Divinski I.
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S37-41. PubMed ID: 15665412
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Peptide neuroprotection through specific interaction with brain tubulin.
    Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I.
    J Neurochem; 2006 Aug; 98(3):973-84. PubMed ID: 16893427
    [Abstract] [Full Text] [Related]

  • 6. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).
    Gozes I.
    Curr Pharm Des; 2011 Aug; 17(31):3413-7. PubMed ID: 21902667
    [Abstract] [Full Text] [Related]

  • 7. NAP protects against cyanide-related microtubule destruction.
    Zemlyak I, Sapolsky R, Gozes I.
    J Neural Transm (Vienna); 2009 Nov; 116(11):1411-6. PubMed ID: 19551468
    [Abstract] [Full Text] [Related]

  • 8. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
    Shiryaev N, Pikman R, Giladi E, Gozes I.
    Curr Pharm Des; 2011 Nov; 17(25):2603-12. PubMed ID: 21728979
    [Abstract] [Full Text] [Related]

  • 9. Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy.
    Ivashko-Pachima Y, Gozes I.
    Prog Mol Biol Transl Sci; 2021 Nov; 177():65-90. PubMed ID: 33453943
    [Abstract] [Full Text] [Related]

  • 10. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).
    Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L.
    CNS Drug Rev; 2005 Nov; 11(4):353-68. PubMed ID: 16614735
    [Abstract] [Full Text] [Related]

  • 11. The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules.
    Yenjerla M, LaPointe NE, Lopus M, Cox C, Jordan MA, Feinstein SC, Wilson L.
    J Alzheimers Dis; 2010 Nov; 19(4):1377-86. PubMed ID: 20061604
    [Abstract] [Full Text] [Related]

  • 12. NAP alpha-aminoisobutyric acid (IsoNAP).
    Gozes I, Schirer Y, Idan-Feldman A, David M, Furman-Assaf S.
    J Mol Neurosci; 2014 Jan; 52(1):1-9. PubMed ID: 24458740
    [Abstract] [Full Text] [Related]

  • 13. Power of Tyrosine Assembly in Microtubule Stabilization and Neuroprotection Fueled by Phenol Appendages.
    Barman S, Das G, Mondal P, Pradhan K, Bhunia D, Khan J, Kar C, Ghosh S.
    ACS Chem Neurosci; 2019 Mar 20; 10(3):1506-1516. PubMed ID: 30565916
    [Abstract] [Full Text] [Related]

  • 14. NAP protects against cytochrome c release: inhibition of the initiation of apoptosis.
    Zemlyak I, Sapolsky R, Gozes I.
    Eur J Pharmacol; 2009 Sep 15; 618(1-3):9-14. PubMed ID: 19619522
    [Abstract] [Full Text] [Related]

  • 15. Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.
    Gozes I.
    Peptides; 2011 Feb 15; 32(2):428-31. PubMed ID: 21050875
    [Abstract] [Full Text] [Related]

  • 16. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.
    Oz S, Ivashko-Pachima Y, Gozes I.
    PLoS One; 2012 Feb 15; 7(12):e51458. PubMed ID: 23272107
    [Abstract] [Full Text] [Related]

  • 17. The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins.
    Oz S, Kapitansky O, Ivashco-Pachima Y, Malishkevich A, Giladi E, Skalka N, Rosin-Arbesfeld R, Mittelman L, Segev O, Hirsch JA, Gozes I.
    Mol Psychiatry; 2014 Oct 15; 19(10):1115-24. PubMed ID: 25178163
    [Abstract] [Full Text] [Related]

  • 18. NAP protects hippocampal neurons against multiple toxins.
    Zemlyak I, Manley N, Sapolsky R, Gozes I.
    Peptides; 2007 Oct 15; 28(10):2004-8. PubMed ID: 17869381
    [Abstract] [Full Text] [Related]

  • 19. NAP (davunetide) provides functional and structural neuroprotection.
    Gozes I.
    Curr Pharm Des; 2011 Oct 15; 17(10):1040-4. PubMed ID: 21524250
    [Abstract] [Full Text] [Related]

  • 20. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.
    Ivashko-Pachima Y, Sayas CL, Malishkevich A, Gozes I.
    Mol Psychiatry; 2017 Sep 15; 22(9):1335-1344. PubMed ID: 28115743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.